Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study has been designed as a randomized, double-blind, controlled, study to evaluate the
efficacy and safety of two once daily intravenous peramivir regimens (200 mg and 400 mg)
versus oral oseltamivir phosphate (75 mg twice daily) in hospitalized subjects with acute
serious or potentially life threatening influenza. Study treatments will be provided for up
to 5 consecutive days.